NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AIM

AIM ImmunoTech Inc

Jul 03 • 04:00PM ET

8.85

Dollar change -0.32
Percentage change -3.47	%

Healthcare • Biotechnology • USA • AMEX

Peers: JNJ LLY PFE AZN MRNA BMY GILD AMGN REGN VRTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-24.80	Insider Own	16.00%	Shs Outstand	0.72M	Perf Week	-7.56%
Market Cap	6.76M	Forward P/E	-	EPS next Y	-31.00	Insider Trans	195.42%	Shs Float	0.64M	Perf Month	20.82%
Enterprise Value	7.03M	PEG	-	EPS next Q	-8.00	Inst Own	6.32%	Short Float	1.53%	Perf Quarter	-29.20%
Income	-15.21M	P/S	45.07	EPS this Y	0.00%	Inst Trans	2.25%	Short Ratio	1.27	Perf Half Y	-57.51%
Sales	0.15M	P/B	-	EPS next Y	0.00%	ROA	-135.56%	Short Interest	0.01M	Perf YTD	-55.30%
Book/sh	-5.34	P/C	3.00	EPS next 5Y	-	ROE	-3138.91%	52W High	42.95 -79.39%	Perf Year	-76.25%
Cash/sh	2.95	P/FCF	-	EPS past 3/5Y	8.53% 34.59%	ROIC	-	52W Low	2.51 252.59%	Perf 3Y	-89.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.99% 3.96%	Gross Margin	-91.10%	Volatility	6.80% 18.97%	Perf 5Y	-96.46%
Dividend TTM	-	EV/Sales	46.87	EPS Y/Y TTM	61.00%	Oper. Margin	-11863.01%	ATR (14)	1.33	Perf 10Y	-99.92%
Dividend Ex-Date	-	Quick Ratio	0.26	Sales Y/Y TTM	-24.35%	Profit Margin	-10416.44%	RSI (14)	51.72	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.26	EPS Q/Q	55.21%	SMA20	4.50%	Beta	0.92	Target Price	150.00
Payout	-	Debt/Eq	-	Sales Q/Q	-60.00%	SMA50	7.17%	Rel Volume	0.47	Prev Close	9.17
Employees	23	LT Debt/Eq	-	Earnings	May 15	SMA200	-46.10%	Avg Volume	7.70K	Price	8.85
IPO	Jul 15, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	3,647	Change	-3.47%

Jul-02-25 08:55AM	AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies (GlobeNewswire)
Jun-20-25 04:15PM	AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements (GlobeNewswire) -9.26%
Jun-17-25 08:55AM	AIM ImmunoTech Resumes Trading on NYSE American (GlobeNewswire) +6.84%
Apr-07-25 01:26PM	AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market (GlobeNewswire) -57.53%
Apr-04-25 04:45PM	AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal (GlobeNewswire) -19.37%
08:05AM	Loading…
Mar-27-25 08:05AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Equels Thomas K	CEO & President	Apr 04 '25	Buy	0.06	41,000	2,583	1,899,029	Apr 07 03:42 PM
Rodino Peter W III	COO, Secretary, Gen. Counsel	Apr 04 '25	Buy	0.09	500	44	401,762	Apr 04 05:19 PM
Equels Thomas K	CEO & President	Mar 05 '25	Buy	0.13	50,000	6,730	1,858,029	Mar 06 09:36 AM
Equels Thomas K	CEO & President	Mar 04 '25	Buy	0.12	44,000	5,060	1,808,029	Mar 05 10:00 AM
Equels Thomas K	CEO & President	Mar 04 '25	Buy	0.12	83,334	10,000	1,764,029	Mar 04 01:14 PM
Equels Thomas K	CEO & President	Nov 21 '24	Buy	0.21	20,000	4,240	1,657,968	Jan 21 04:32 PM
MITCHELL WILLIAM M	Director	Dec 19 '24	Sale	0.19	4,580	884	118,549	Dec 20 04:30 PM
Equels Thomas K	CEO & President	Dec 18 '24	Buy	0.21	22,727	4,682	1,680,695	Dec 19 01:38 PM
APPELROUTH STEWART	Director	Dec 02 '24	Buy	0.21	11,112	2,356	355,509	Dec 04 04:05 PM
Equels Thomas K	CEO & President	Nov 20 '24	Buy	0.20	85,000	16,915	1,637,968	Nov 21 12:04 PM
APPELROUTH STEWART	Director	Nov 20 '24	Buy	0.19	81,953	15,817	321,752	Nov 21 12:02 PM
Equels Thomas K	CEO & President	Nov 20 '24	Buy	0.18	60,110	11,000	1,552,968	Nov 20 12:46 PM
Equels Thomas K	CEO & President	Sep 16 '24	Buy	0.30	5,000	1,515	1,493,042	Sep 17 12:05 PM
Equels Thomas K	CEO & President	Sep 13 '24	Buy	0.31	20,000	6,160	1,488,042	Sep 16 03:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIM

AIM ImmunoTech Inc

Upgrade your FINVIZ experience